FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
BioSpace2d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Seeking Alpha2d
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
healthday5d
FDA Approves Cobenfy for Adults With Schizophrenia
THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of ...
Zacks Small Cap Research on MSN17h
RVPH: Year-End OLE Update
RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...
Investing4d
EMA committee recommends repotrectinib for lung cancer
Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian. Furthermore, Bristol-Myers Squibb's Phase 3 EMERGENT-4 and EMERGENT-5 ...
FiercePharma6d
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...